Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has shared an announcement.
Venus Medtech (Hangzhou) Inc. has informed shareholders that Cardiovalve Ltd. and MTH IP, L.P. have filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Edwards Lifesciences over U.S. Patent No. 10,702,385, covering an implant for heart valves. The case, which targets Edwards’ PASCAL Precision Transcatheter Valve Repair System and follows a prior U.S. Federal Circuit decision upholding the patent’s key claims, remains at an early stage with potential claim amounts and outcomes still uncertain, and Venus Medtech has cautioned investors to exercise care when trading its shares as it monitors developments and plans further updates as required under Hong Kong listing rules.
The most recent analyst rating on (HK:2500) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Venus Medtech (Hangzhou), Inc. Class H stock, see the HK:2500 Stock Forecast page.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a PRC-incorporated medical technology company listed in Hong Kong that operates in the cardiovascular device sector, focusing on innovative heart valve implants and related transcatheter therapies aimed at treating structural heart diseases in global markets.
Average Trading Volume: 1,969,855
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.57B
See more data about 2500 stock on TipRanks’ Stock Analysis page.